Under this program, patients with progressive gastric cancer cancerwho are referred by our partner clinics can receive exams, diagnoses, and surgery dates on just a single visit. This program aims to provide quick diagnoses and treatment for progressive gastric cancer cancerpatients, which guarantees optimal care and great satisfaction among the patients and their families by reducing anxiety. We do our best to assign the earliest possible surgery dates, and when anticancer therapies are considered necessary, specialists in diverse disciplines join and discuss the best possible regimen.

Gastroscopy, abdominal CT (stomach imaging and virtual gastroscopy), PET, blood testing, thoracic imaging, physiological tests, ultrasonography, MRI, etc.

Surgery is the most fundamental treatment and performed in the form of laparotomy, laparoscopic surgery, and robotic surgery. Fully set up with gastric cancer experts, operating rooms for laparoscopic and robotic surgery and multi-disciplinary operations, a dedicated ward, and a multi-disciplinary system, the Center boasts solid treatment outcomes as well as growing number of surgery.
Endoscopic submucosal dissection is well recognized as a standard treatment for precancerous lesions like gastric adenoma and early-stage stomach cancer whose lesions are small and well differentiated.
We also provide post-surgery adjuvant chemo and radiotherapies as well as diverse conventional therapies against progressive or relapsing stomach cancer to improve the survival rate and the patients’ quality of life. At the same time, we perform a wide range of clinical research to help chart a future direction of cancer treatment.

Thanks to a recent advance in molecular biology and oncology, blanket application of chemotherapy to every patient and type is no longer recommended. Now, there is a growing demand for personalized therapies based on patients’ genomic information, namely their individual genomic mutations. We can expect much better results by sorting out patients who may respond to targeted molecular agents.
This targeted therapy has been actively studied for stomach cancer, too, and it has been tested to combine conventional chemotherapies with the targeted agents such as angiogenesis inhibitors and epidermal growth factor inhibitors. According to a recent study, it has been noted that progressive stomach cancer patients who were identified with over-expression or amplification of the HER2 gene showed significantly improved outcomes after treated with Herceptin in addition to conventional chemotherapies. Therefore, the targeted combination of Herceptin and conventional anticancer agents is currently considered a standard.

Gastric Cancer Center operates a variety of programs that enhance the quality of life for gastric cancer patients and their families. In addition, we are publishing and distributing gastric cancer information booklets so that we can answer some of the questions asked by gastric cancer patients and to help patients resolve and settle any confusions. We routinely conduct education programs for gastric cancer patients to answer their questions. We are running an Internet community for gastric cancer patients to help our patients manage their daily lives and exchange accurate information. We also have a gastric cancer mentoring program where patients recently diagnosed with gastric cancer get help from those who have been suffering from the same disease for a longer period.